The diagnostic value of assays for circulating tumor cells in hepatocellular carcinoma

Sun, Chenglong; Liao, Wenjun; Deng, Zefu; Li, Enliang; Feng, Qian; Lei, Jun; Yuan, Rongfa; Zou, Shubing; Mao, Yilei; Shao, Jianghua; Wu, Linquan; Zhang, Chao

doi:10.1097/md.0000000000007513

Cited by 44 publications

(32 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Detection of CTCs is associated with poor overall survival and relapse-free survival [91] . In addition to that, CTCs positivity is significantly correlated with serum AFP level, vascular invasion and TNM stage which can reflect the histopathological status of HCC [92] . According to a recent meta-analysis of more than 20 studies, the CTC is not used as a sole indicator for diagnosis instead associated with poor clinical and pathological features [92] .…”

Section: Ctcsmentioning

confidence: 90%

New and old biomarkers of hepatocellular carcinoma

Zacharakis¹,

AlEid²,

Aldossari³

2018

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is a significant cause of mortality in patients with chronic liver disease around the world. Development of biomarkers for early HCC detection is a primary public health goal to decrease mortality. The ideal biomarkers should be highly sensitive and specific for surveillance of high-risk populations and early detection of HCC and also be able to predict therapeutic outcome and provide a prognosis on survival. Currently, the new biomarkers do not perform better than the conventional ones such as alpha-fetoprotein in such a way that they could be widely adopted in clinical practice. Another problem is the low sensitivity of these biomarkers in the detection of HCC. Further work on the development of novel biomarkers and on a combination of them is necessary. Advances in identifying unique molecular signatures including genomic, proteomic, metabolomic, and glycomic profiles have improved our understanding of many biological processes involved in HCC. This review focuses on the role of old and new biomarkers in surveillance, diagnosis, prognosis, and prediction of response to therapeutic targets for HCC and provides up-to-date data to health-care providers which would be applied in clinical practice.

show abstract

Section: Ctcsmentioning

confidence: 90%

New and old biomarkers of hepatocellular carcinoma

Zacharakis¹,

AlEid²,

Aldossari³

2018

View full text Add to dashboard Cite

show abstract

“…Given the highly vascularized liver environment, the use of CTCs as biomarkers for HCC has been under scrutiny. For instance, two different meta-analyses have shown that CTCs associate with a poor prognosis and poor clinicopathologic parameters in HCC [58,59]. Epithelial-mesenchymal-mixed CTCs seem to play an important role in epithelial-mesenchymal transition in HCC, mixed CTCs appearing to play a vital factor for intrahepatic metastasis, and mesenchymal CTCs having the potential to predict extrahepatic metastasis [60].…”

Section: Circulating Tumor Cells and Extracellular Vesiclesmentioning

confidence: 99%

Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning?

Mocan

Simão

Castro

et al. 2020

JCM

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) represents the sixth most common cancer worldwide and the third most common cause of cancer-related death. One of the major problems faced by researchers and clinicians in this area is the lack of reliable disease biomarkers, which would allow for an earlier diagnosis, follow-up or prediction of treatment response, among others. In this regard, the “HCC circulome”, defined as the pool of circulating molecules in the bloodstream derived from the primary tumor, represents an appealing target, the so called liquid biopsy. Such molecules encompass circulating tumor proteins, circulating tumor cells (CTCs), extracellular vesicles (EVs), tumor-educated platelets (TEPs), and circulating tumor nucleic acids, namely circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA). In this article, we summarize recent findings highlighting the promising role of liquid biopsies as novel potential biomarkers in HCC, emphasizing on its clinical performance.

show abstract

“…A correlation exists between the postoperative early recurrence of HCC and mesenchymal CTCs [32,33]. An elevated number of CTCs is associated with unfavorable clinicopathologic characteristics responsible for poor prognosis in patients with HCC [34]. An increase in the number of postoperative CTCs when compared to the number of preoperative CTCs is associated with lower survival and higher recurrence among patients with low AFP levels and cirrhosis [35].…”

Section: Discussionmentioning

confidence: 99%

Sequential Circulating Tumor Cell Counts in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: Monitoring the Treatment Response

Rau

Liu

Hsiao

et al. 2020

JCM

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is among the most common causes of cancer death in men. Whether or not a longitudinal follow-up of circulating tumor cells (CTCs) before and at different time points during systemic/targeted therapy is useful for monitoring the treatment response of patients with locally advanced or metastatic HCC has been evaluated in this study. Blood samples (n = 104) were obtained from patients with locally advanced or metastatic HCC (n = 30) for the enrichment of CTCs by a negative selection method. Analysis of the blood samples from patients with defined disease status (n = 81) revealed that those with progressive disease (PD, n = 37) had significantly higher CTC counts compared to those with a partial response (PR) or stable disease (SD; n = 44 for PR + SD, p = 0.0002). The median CTC count for patients with PD and for patients with PR and SD was 50 (interquartile range 21–139) and 15 (interquartile range 4–41) cells/mL of blood, respectively. A longitudinal analysis of patients (n = 17) after a series of blood collections demonstrated that a change in the CTC count correlated with the patient treatment response in most of the cases and was particularly useful for monitoring patients without elevated serum alpha-fetoprotein (AFP) levels. Sequential CTC enumeration during treatment can supplement standard medical tests and benefit the management of patients with locally advanced or metastatic HCC, in particular for the AFP-low cases.

show abstract

The diagnostic value of assays for circulating tumor cells in hepatocellular carcinoma

Abstract: Supplemental Digital Content is available in the text

Cited by 44 publications

References 46 publications

New and old biomarkers of hepatocellular carcinoma

New and old biomarkers of hepatocellular carcinoma

Liquid Biopsies in Hepatocellular Carcinoma: Are We Winning?

Sequential Circulating Tumor Cell Counts in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: Monitoring the Treatment Response

Contact Info

Product

Resources

About